Compare SPRO & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | ZVIA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 126.3M |
| IPO Year | 2017 | 2021 |
| Metric | SPRO | ZVIA |
|---|---|---|
| Price | $1.58 | $1.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.93 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 55.88 |
| EPS | N/A | ★ N/A |
| Revenue | $66,802,000.00 | ★ $161,259,000.00 |
| Revenue This Year | N/A | $8.30 |
| Revenue Next Year | $300.00 | $6.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | 4.01 |
| 52 Week Low | $1.52 | $1.11 |
| 52 Week High | $3.08 | $3.63 |
| Indicator | SPRO | ZVIA |
|---|---|---|
| Relative Strength Index (RSI) | 26.06 | 55.73 |
| Support Level | N/A | $1.60 |
| Resistance Level | $2.45 | $1.94 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 8.93 | 40.74 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.